Filter

Refine by collections

  • Growth Hormone in Endocrine Cancers (11)

Refine by date

—

Refine by access

  • Print
  • Save

Search Results

You are looking at 1 - 10 of 11 items for :

  • prostate cancer x
  • Growth Hormone in Endocrine Cancers x
  • Refine by access: All content x
Clear All
Xi Zhang Shenzhen Bay Laboratory, Shenzhen, P R China

Search for other papers by Xi Zhang in
Google Scholar
PubMed Close
,
Vijay Pandey Tsinghua Berkeley Shenzhen Institute and Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, P R China

Search for other papers by Vijay Pandey in
Google Scholar
PubMed Close
,
Vipul Bhardwaj Tsinghua Berkeley Shenzhen Institute and Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, P R China

Search for other papers by Vipul Bhardwaj in
Google Scholar
PubMed Close
,
Tao Zhu Shenzhen Bay Laboratory, Shenzhen, P R China
Department of Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, P R China
The CAS Key Laboratory of Innate Immunity and Chronic Disease, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, P R China

Search for other papers by Tao Zhu in
Google Scholar
PubMed Close
, and
Peter E Lobie Shenzhen Bay Laboratory, Shenzhen, P R China
Tsinghua Berkeley Shenzhen Institute and Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, P R China

Search for other papers by Peter E Lobie in
Google Scholar
PubMed Close

reduce GH expression in mouse models of breast cancer ( Szepeshazi et al. 2001 ). In human prostate carcinoma cells, androgens downregulate hGH expression, and hGH expression is increased in cells with acquired resistance to enzalutamide, a second

Article Type:
Review Article
Collections:
Growth Hormone in Endocrine Cancers
DOI:
https://doi.org/10.1530/ERC-23-0120
Volume/Issue:
Volume 31: Issue 1
Restricted access
Paul C Marker School of Pharmacy, Pharmaceutical Sciences Division, University of Wisconsin-Madison, Madison, Wisconsin, USA

Search for other papers by Paul C Marker in
Google Scholar
PubMed Close
,
Christopher J Unterberger School of Pharmacy, Pharmaceutical Sciences Division, University of Wisconsin-Madison, Madison, Wisconsin, USA

Search for other papers by Christopher J Unterberger in
Google Scholar
PubMed Close
, and
Steven M Swanson School of Pharmacy, Pharmaceutical Sciences Division, University of Wisconsin-Madison, Madison, Wisconsin, USA

Search for other papers by Steven M Swanson in
Google Scholar
PubMed Close

can also be generated by non-liver tissue and act locally (A5). (B) GH also acts independently of IGF-1 by activating GHR on target tissues (shown here as prostate, mammary duct, and cancer cells). Figure created at https

Article Type:
Review Article
Collections:
Growth Hormone in Endocrine Cancers
DOI:
https://doi.org/10.1530/ERC-22-0403
Volume/Issue:
Volume 30: Issue 5
Free access
Jaime Guevara-Aguirre Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Diego de Robles s/n y Pampite, Cumbayá, Quito, Ecuador
Instituto de Endocrinología IEMYR, Quito, Ecuador
Maastricht University, Maastricht, The Netherlands

Search for other papers by Jaime Guevara-Aguirre in
Google Scholar
PubMed Close
,
Gabriela Peña Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Diego de Robles s/n y Pampite, Cumbayá, Quito, Ecuador

Search for other papers by Gabriela Peña in
Google Scholar
PubMed Close
,
Gabriel Pazmiño Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Diego de Robles s/n y Pampite, Cumbayá, Quito, Ecuador

Search for other papers by Gabriel Pazmiño in
Google Scholar
PubMed Close
,
William Acosta Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Diego de Robles s/n y Pampite, Cumbayá, Quito, Ecuador

Search for other papers by William Acosta in
Google Scholar
PubMed Close
,
Jannette Saavedra Instituto de Endocrinología IEMYR, Quito, Ecuador

Search for other papers by Jannette Saavedra in
Google Scholar
PubMed Close
,
Daniela Lescano Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Diego de Robles s/n y Pampite, Cumbayá, Quito, Ecuador

Search for other papers by Daniela Lescano in
Google Scholar
PubMed Close
,
Alexandra Guevara Instituto de Endocrinología IEMYR, Quito, Ecuador

Search for other papers by Alexandra Guevara in
Google Scholar
PubMed Close
, and
Antonio W D Gavilanes Maastricht University, Maastricht, The Netherlands

Search for other papers by Antonio W D Gavilanes in
Google Scholar
PubMed Close

12% higher incidence of BC, while no increase in pancreatic, colorectal, and prostate cancer was noted ( Soltani et al. 2021 ). Namazi and colleagues evaluated 12 studies describing 251,045 subjects. Combined adjusted multivariable relative risk

Article Type:
Review Article
Collections:
Growth Hormone in Endocrine Cancers
DOI:
https://doi.org/10.1530/ERC-22-0389
Volume/Issue:
Volume 30: Issue 6
Free access
Cesar Luiz Boguszewski Department of Internal Medicine, Endocrine Division (SEMPR), University Hospital, Federal University of Parana, Curitiba, Brazil

Search for other papers by Cesar Luiz Boguszewski in
Google Scholar
PubMed Close
,
Margaret Cristina da Silva Boguszewski Department of Pediatrics, Endocrine Division (SEMPR), University Hospital, Federal University of Parana, Curitiba, Brazil

Search for other papers by Margaret Cristina da Silva Boguszewski in
Google Scholar
PubMed Close
, and
Wouter W de Herder Department of Internal Medicine, Sector of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands

Search for other papers by Wouter W de Herder in
Google Scholar
PubMed Close

that metastases could be suppressed after hypophysectomy led to treatment of advanced cancers in humans, particularly those of the breast and prostate, with surgical ablation of the pituitary, mainly in the 1950s and early1960s ( Bailey 1956 ). At that

Article Type:
Review Article
Collections:
Growth Hormone in Endocrine Cancers
DOI:
https://doi.org/10.1530/ERC-22-0400
Volume/Issue:
Volume 30: Issue 4
Free access
Reetobrata Basu Edison Biotechnology Institute, Athens, Ohio, USA

Search for other papers by Reetobrata Basu in
Google Scholar
PubMed Close
and
John J Kopchick Edison Biotechnology Institute, Athens, Ohio, USA
Molecular and Cellular Biology Program, Ohio University, Athens, Ohio, USA
Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, USA

Search for other papers by John J Kopchick in
Google Scholar
PubMed Close

high degree of sequence similarity of human GH and PRL ( Xu et al. 2013 ). In several cancers like that of the breast and prostate, PRLR expression is often found upregulated and inversely correlated with survival. In such cancers, GH is expected to

Article Type:
Review Article
Collections:
Growth Hormone in Endocrine Cancers
DOI:
https://doi.org/10.1530/ERC-22-0414
Volume/Issue:
Volume 30: Issue 9
Free access
Jaime Guevara-Aguirre Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Diego de Robles s/n y Pampite, Cumbayá, Quito, Ecuador
Instituto de Endocrinología IEMYR, Quito, Ecuador
Maastricht University, Maastricht, The Netherlands

Search for other papers by Jaime Guevara-Aguirre in
Google Scholar
PubMed Close
,
Gabriela Peña Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Diego de Robles s/n y Pampite, Cumbayá, Quito, Ecuador

Search for other papers by Gabriela Peña in
Google Scholar
PubMed Close
,
William Acosta Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Diego de Robles s/n y Pampite, Cumbayá, Quito, Ecuador

Search for other papers by William Acosta in
Google Scholar
PubMed Close
,
Gabriel Pazmiño Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Diego de Robles s/n y Pampite, Cumbayá, Quito, Ecuador

Search for other papers by Gabriel Pazmiño in
Google Scholar
PubMed Close
,
Jannette Saavedra Instituto de Endocrinología IEMYR, Quito, Ecuador

Search for other papers by Jannette Saavedra in
Google Scholar
PubMed Close
,
Lina Soto Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Diego de Robles s/n y Pampite, Cumbayá, Quito, Ecuador

Search for other papers by Lina Soto in
Google Scholar
PubMed Close
,
Daniela Lescano Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Diego de Robles s/n y Pampite, Cumbayá, Quito, Ecuador

Search for other papers by Daniela Lescano in
Google Scholar
PubMed Close
,
Alexandra Guevara Instituto de Endocrinología IEMYR, Quito, Ecuador

Search for other papers by Alexandra Guevara in
Google Scholar
PubMed Close
, and
Antonio W D Gavilanes Maastricht University, Maastricht, The Netherlands

Search for other papers by Antonio W D Gavilanes in
Google Scholar
PubMed Close

follows: lung (0.8; 95% CI, 0.5–1.2), prostate (1.2; 95% CI, 0.8–1.9), and hematological cancers (1.3; 95% CI, 0.8–2.3). Based on a review of the literature, Boguszewski & Ayuk (2016) concluded that thyroid cancer behaves not differently in acromegalic

Article Type:
Review Article
Collections:
Growth Hormone in Endocrine Cancers
DOI:
https://doi.org/10.1530/ERC-22-0402
Volume/Issue:
Volume 30: Issue 10
Free access
Christopher A Galifi Department of Pharmacology, Physiology, & Neuroscience, Center for Cell Signaling and Cancer Institute of New Jersey, Rutgers Biomedical and Health Sciences, Newark, New Jersey, United States

Search for other papers by Christopher A Galifi in
Google Scholar
PubMed Close
and
Teresa L Wood Department of Pharmacology, Physiology, & Neuroscience, Center for Cell Signaling and Cancer Institute of New Jersey, Rutgers Biomedical and Health Sciences, Newark, New Jersey, United States

Search for other papers by Teresa L Wood in
Google Scholar
PubMed Close

overexpression in various cancers, including pancreatic and prostate cancer ( Bohula et al. 2003 , Riedemann & Macaulay 2006 ). Functionally, IGF1R plays a well-established role in promoting the proliferation of various cell types and cancers ( Baserga et al

Article Type:
Review Article
Collections:
Growth Hormone in Endocrine Cancers
DOI:
https://doi.org/10.1530/ERC-23-0031
Volume/Issue:
Volume 30: Issue 10
Free access
Zvi Laron Endocrinology and Diabetes Research Unit, Schneider Children’s Medical Center, Petah Tikva, Israel

Search for other papers by Zvi Laron in
Google Scholar
PubMed Close
and
Haim Werner Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

Search for other papers by Haim Werner in
Google Scholar
PubMed Close

risk for breast, prostate, lung, sarcoma and colorectal cancer. These reports highlighted the cardinal role of the GH–IGF-1 axis in cancer etiology. Therefore, it was of basic and clinical interest to investigate the impact of lifelong IGF-1 deficiency

Article Type:
Review Article
Collections:
Growth Hormone in Endocrine Cancers
DOI:
https://doi.org/10.1530/ERC-22-0394
Volume/Issue:
Volume 30: Issue 9
Free access
Yue Wang Liggins Institute, University of Auckland, Auckland, New Zealand
Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand

Search for other papers by Yue Wang in
Google Scholar
PubMed Close
,
Stephen M F Jamieson Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand
Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand
Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand

Search for other papers by Stephen M F Jamieson in
Google Scholar
PubMed Close
, and
Jo K Perry Liggins Institute, University of Auckland, Auckland, New Zealand
Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand

Search for other papers by Jo K Perry in
Google Scholar
PubMed Close

include breast, colorectal, meningeal, prostate, endometrial gastric, pancreatic and hepatocellular cancer ( McCutcheon et al. 2001 , Dagnaes-Hansen et al. 2004 , Divisova et al. 2006 , Lombardi et al. 2014 , Evans et al. 2016 , Brody et al

Article Type:
Review Article
Collections:
Growth Hormone in Endocrine Cancers
DOI:
https://doi.org/10.1530/ERC-23-0033
Volume/Issue:
Volume 30: Issue 9
Free access
Melissa Bolier Department of Internal Medicine, section Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

Search for other papers by Melissa Bolier in
Google Scholar
PubMed Close
,
Aart-Jan van der Lelij Department of Internal Medicine, section Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands

Search for other papers by Aart-Jan van der Lelij in
Google Scholar
PubMed Close
,
Geert O Janssens Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands

Search for other papers by Geert O Janssens in
Google Scholar
PubMed Close
,
Marry M van den Heuvel-Eibrink Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands

Search for other papers by Marry M van den Heuvel-Eibrink in
Google Scholar
PubMed Close
, and
Sebastian J C M M Neggers Department of Internal Medicine, section Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands

Search for other papers by Sebastian J C M M Neggers in
Google Scholar
PubMed Close

Introduction There has been a significant improvement in the outcomes of childhood cancer over the past decades, now exceeding a 5-year survival rate of 80% in western countries ( Gatta et al. 2014 ). However, these survivors are already at

Article Type:
Review Article
Collections:
Growth Hormone in Endocrine Cancers
DOI:
https://doi.org/10.1530/ERC-23-0026
Volume/Issue:
Volume 30: Issue 7
Free access